Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)

Phase 3

Recruiting

• Conditions: Allergy; Peanut Allergy

• Registration Number: NCT07003919
• Lead Sponsor: DBV Technologies

Brief Summary

The primary objective of this study is to assess the 6-month safety of DBV712 250 micrograms (mcg) in subjects 1 through 3 years of age with peanut allergy.

Detailed Description

This is a Phase 3 randomized double-blind, placebo-controlled (DBPC) study of 6-months duration to assess the safety of DBV712 250 mcg in subjects 1 through 3 years of age with peanut allergy. Participants who complete the 6-month DBPC period will be eligible to enter an optional 18-month open-label extension (OLE).

The overall maximum study duration for each participant will be approximately 112 weeks: Screening Period of 6-weeks, DBPC Treatment Period of 26-weeks, Open-label Period of 78-weeks and Follow-up Period of 2-weeks.

For participation eligibility, please refer to eligibility criteria section.

Randomization of eligible participants will occur in a 3:1 ratio to DBV712 250 mcg (active treatment) or placebo, respectively.

Study Timeline

• Study First Submitted: 2025-05-27
• Study First Submitted QC: 2025-05-27
• Study First Posted: 2025-06-04
• Study Start: 2025-06-24
• Status Verified: 2025-08
• Last Update Submitted: 2025-08-11
• Last Update Posted: 2025-08-14
• Primary Completion: 2026-11
• Study Completion: 2028-05-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 480

Inclusion Criteria

• Aged 1 through 3 years at Visit 1 (screening).
• Physician-diagnosed peanut allergy and following a strict peanut-free diet
• Peanut-specific IgE > 0.7 kUA/L.
• A positive peanut SPT with the largest wheal diameter of ≥ 6 mm at Visit 1 (screening).
• An ED ≤ 300 mg peanut protein at screening double-blind placebo-controlled food challenge (DBPCFC).

Key

Exclusion Criteria

• Peanut allergic subjects presenting a medical history of severe anaphylaxis to peanut.
• Severe generalized dermatologic disease involving the proposed treatment application area (interscapular region).
• Current immunotherapy for any allergen (including food allergy, allergic rhinitis and/or insect allergy).
• History of any immunotherapy for peanut allergy, including Epicutaneous immunotherapy (EPIT), oral immunotherapy (OIT), sublingual immunotherapy (SLIT).
• Treatment with any monoclonal antibody or biologic immunomodulatory therapy within 6 months prior to Visit 1.
• Uncontrolled persistent asthma.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
DBPC Treatment Period: Adverse Events (AEs), Treatment-Emergent Adverse Events (TEAEs), and Serious Adverse Events (SAEs)	Through DBPC Treatment Period, 6 months

Trial Locations

Locations (58)

AllerVie Clinical Research; 🇺🇸 Birmingham, Alabama, United States

University of Alabama at Birmingham Pediatric Primary Care Clinic; 🇺🇸 Birmingham, Alabama, United States

University of Arizona Asthma and Airway Disease Research Center; 🇺🇸 Tucson, Arizona, United States

Arkansas Children's Hospital; 🇺🇸 Little Rock, Arkansas, United States

Modena Allergy & Asthma; 🇺🇸 La Jolla, California, United States

UCLA Health Westwood Pediatrics; 🇺🇸 Los Angeles, California, United States

Allergy & Asthma Associates of Southern California; 🇺🇸 Mission Viejo, California, United States

Lucile Packard Children's Hospital Stanford; 🇺🇸 Palo Alto, California, United States

Allergy & Asthma Medical Group and Research Center; 🇺🇸 San Diego, California, United States

Rady Children's Hospital - San Diego; 🇺🇸 San Diego, California, United States

Scroll for more (48 remaining)